{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:56:20Z","timestamp":1770965780656,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Institutes of Health Research (CIHR)"},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.025","type":"journal-article","created":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T13:14:57Z","timestamp":1466255697000},"page":"4046-4049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study"],"prefix":"10.1016","volume":"34","author":[{"given":"J.M.","family":"Langley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.A.","family":"Top","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"MacKinnon-Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Serres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2016.06.025_b0005","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.06.025_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000\u20132010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2016.06.025_b0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/IPC.0000000000000197","article-title":"Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for infectious diseases","author":"Schaffner","year":"2014","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.vaccine.2016.06.025_b0020","unstructured":"Department of Health and Wellness Government of Nova Scotia. Meningitis B vaccinations for Acadia; 2015. Available from: <http:\/\/novascotia.ca\/news\/release\/?id=20150213001> [cited 2015 February 13, 2015, press release]."},{"key":"10.1016\/j.vaccine.2016.06.025_b0025","series-title":"The recommended use of the multicomponent Meningococcal serogroup B (4CMenB) vaccine in Canada: a common guidance statement","first-page":"77","author":"Meningococcal B pilot task group","year":"2014"},{"issue":"9816","key":"10.1016\/j.vaccine.2016.06.025_b0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2016.06.025_b0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vacc Immunol"},{"key":"10.1016\/j.vaccine.2016.06.025_b0040","unstructured":"Vaccines blood and biologics U.S. Food and Drug Administration. Summary Basis for Regulatory Action (SBRA) \u2013 Bexsero; 2015 23 February 2015. Available from: <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM434748.pdf> [cited 2015 23 February 2015]."},{"key":"10.1016\/j.vaccine.2016.06.025_b0045","series-title":"Initial dose of a multicomponent serogroup b Meningococcal Vaccine in the Saguenay-Lac-Saint-Jean Region, Quebec, Canada: an interim safety surveillance report","author":"de Serres","year":"2014"},{"issue":"RR-2","key":"10.1016\/j.vaccine.2016.06.025_b0050","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2016.06.025_b0055","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/INF.0000000000000373","article-title":"Rapid online identification of adverse events after influenza immunization in children by PCIRN\u2019s National Ambulatory Network","volume":"33","author":"Bettinger","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2016.06.025_b0060","doi-asserted-by":"crossref","first-page":"e38563","DOI":"10.1371\/journal.pone.0038563","article-title":"Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine","volume":"7","author":"De Serres","year":"2012","journal-title":"PLoS ONE"},{"issue":"29","key":"10.1016\/j.vaccine.2016.06.025_b0065","doi-asserted-by":"crossref","first-page":"21189","DOI":"10.2807\/1560-7917.ES2015.20.29.21189","article-title":"Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012","volume":"20","author":"Bettinger","year":"2015","journal-title":"Euro Surveill"},{"issue":"6","key":"10.1016\/j.vaccine.2016.06.025_b0070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1740774511419868","article-title":"Strategies for successful rapid trials of influenza vaccine","volume":"8","author":"Scheifele","year":"2011","journal-title":"Clin Trials"},{"key":"10.1016\/j.vaccine.2016.06.025_b0075","doi-asserted-by":"crossref","first-page":"b4652","DOI":"10.1136\/bmj.b4652","article-title":"Future of flu vaccines. Expediting clinical trials in a pandemic","volume":"339","author":"Pollard","year":"2009","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2016.06.025_b0080","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.6.21035","article-title":"Timeliness of epidemiological outbreak investigations in peer-reviewed European publications, January 2003 to August 2013","volume":"20","author":"van de Venter","year":"2015","journal-title":"Euro Surveill"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:37:37Z","timestamp":1589672257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16304388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":16,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16304388"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}